Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina

Jingjin Li¹, Hong Chen¹*, Jingyi Ren¹, Junxian Song¹, Feng Zhang¹, Jing Zhang¹, Chongyang Lee¹, Sufang Li¹, Qiang Geng¹, Chengfu Cao¹ and Ning Xu²

Abstract

Background: Statin therapy plays a pivotal role in stabilizing the plaque for unstable angina (UA) patients although its mechanism(s) remains largely unexplored. Here we aim to identify microRNAs (miRNAs) mediating the protective effect of statins in UA patients.

Methods: MiRNAs Array was carried out to compare the circulating whole blood miRNA profile of UA patients treated with (n = 10) and without statin (n = 10) and plasma miRNA profile UA patients treated with (n = 5) and without statin (n = 5). 22 whole blood miRNAs and 19 plasma miRNAs were found significantly upregulated in statin group. Targets of these miRNAs were predicted by algorithms: Targetscan, Miranda and Diana microT, then clustered according to functions and cell types by using the Database for Annotation, Visualization and Integrated Discovery (DAVID). To reveal the enriched function pathways in human atherosclerotic plaque, we analyzed microarray data from GEO database, Coronary atherosclerotic plaque (n = 80); macrophages in ruptured plaque (n = 11); carotid atheroma plaque (n = 64); advanced carotid atherosclerotic plaque (n = 29) using Reactome database. Integrated analysis indicated that statin induced miRNAs mainly regulate the signaling pathways of Rho GTPase and hemostasis in human atherosclerotic lesion. In vulnerable plaque, additional immune system signaling was also targeted.

Results: The data showed target genes regulated by these statin induced miRNAs majorly expressed in i) plaque macrophage and platelet, where they were involved in hemostasis process; ii) in monocyte to regulate NGF apoptosis; iii) and in endothelial cell function in Rho GTPase pathway. Integrate analysis indicated that statin induced miRNAs mainly regulate the signaling pathways of Rho GTPase and hemostasis in human atherosclerotic lesion.

Conclusions: Our study suggest that statin induces the expression of multiple miRNAs in the circulation of UA patient, which play important roles by regulating signal pathways critical for the pathogenesis of UA.

Keywords: Unstable angina, Statin, MicroRNA, System biology, Regulatory network

Background

Acute coronary syndrome is the main cause of mortality in the world. Statins are the major prescribed medication for hyperlipidemia, and are also used in the primary and secondary prevention of coronary artery disease. Its main pharmacutic effect is to inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which improves the prognosis of patients. Recently, several experimental and clinical evidences have indicated that statin can also function in cholesterol independent ways [1,2]. For example, it can exert beneficial effect by enhancing endothelial function, suppressing inflammation, improving plaque stability, reducing hemostasis etc. [3,4]. Molecular mechanisms behind the pleiotropic effects of statin, especially in multi-cells and in multi-signaling pathways need to be further investigated. Moreover the post-translation regulation and its functional network during the process remain enigmatic.
MiRNAs are a class of small non-coding RNAs, which can regulate genes via post-translation inhibition by incorporating into the RNA induced silencing complex (RISC) and binding to the 3’ untranslated region (3’UTR) of target miRNAs [5]. Recent studies have demonstrated that miRNAs play important roles in several cardiovascular disorders. miRNAs are also involved in the pathogenesis of plaque lesions, such as to inhibit stability of neointima formation and to decrease the size of plaque, and regulate neovascularization [6-8].

Notably, statin may exert its effect through the downstream signaling pathway via regulating miRNA expression [5]. To study the miRNAs affected by statin treatment, as well as the related gene networks regulated by these miRNAs, we characterized the dynamic change of circulation miRNAome for the UA patients after using miRNA Taqman Low Density Array. Furthermore, bioinformatics analyses were preformed to predict gene targets for these differentially expressed miRNA and to systematically analyze potential function(s) of miRNAs during the development of atherosclerotic in UA patients.

Methods

Study population

Whole blood samples were collected from UA patients (n = 30) enrolled at Peking University People’s Hospital. The protocols were approved by the ethics review board of Peking University People’s Hospital. Informed consent was obtained from each participant. Diagnosis of UA was made according to the ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-Elevation myocardial infarction and the ACC/AHA/ACP-ASIM 1999 guidelines for the management of patients with chronic stable angina. The patients presenting elevated level of troponin I (TNI) and/or creatine kinase (CK-MB), a history of severe hepatic dysfunction, renal dysfunction, leukemia, leukopenia, thrombocytopenia, ongoing inflammatory and malignant diseases were excluded.

Whole blood and plasma sample collection and RNA extraction

Whole blood samples were collected into PAXgene tubes (PreAnalytiX). Blood samples were centrifugation at 1,200 g for 10 minutes at 4°C, plasma were collected from the supernatant then transferred to RNase-free tubes. Samples were store at −80°C right after collection. The RNA was isolated by using preanalytix kit (Qiagen & BD company). Briefly, the pellet centrifuged for 10 min at 3000 g, and resuspended in 350 μl buffer BM1. 40 μl proteinase K and Buffer BM2 were added and incubation continued for 10 min at 55°C. Then transferred to PAXgene Shredder spin column and centrifuged for 3 min at 15,000 g. Supernatant of flowthrough was transferred to microcentrifuge tube, and 700 μl isopropanol was added. The supernatant was loaded on PAXgene RNA spin column to bind total RNA. The total RNA was washed with buffer BM3, and DNA was digested with 10 μl DNasel. RNA was washed with buffer BM3 and buffer BM4, eluted with Buffer BR5, and finally stored at −70°C. Quality of the RNA samples was analyzed by thermo multiskan FC (Thermofisher scientific).

MicroRNAs Taqman low density array

15 ng of total RNAs were reverse transcribed using the Taqman miRNA reverse transcription kit with Taqman miRNA Multiplex RT assays (human pool) (Applied Biosystems, Foster City, CA, USA). The pre-amplification reaction products were then analyzed using Human MicroRNA TaqMan Low Density Arrays (TLDA) version 3.0 (Applied Biosystems). MiRNA expressions were normalized to the expressions of mammal U6, which remained constant in all the samples among different patient groups. Relative quantification software DataAssist was used to calculate miRNAs expression difference with comparative Ct method. To find consistently differentially expressed miRNAs, the data were subjected to significance analysis of microarrays (SAM). MiRNAs with q value <0.0001% were considered to be differentially expressed.

Bioinformatic analyses

The bioinformatic work flow of the study is summarized in supplement Figure 1. miRNA tissue expression profile was retrieved from miRWalk common organ target tools http://www.umc.uni-heidelberg.de/apps/zmf/mirwalk/ [9]. Target prediction of miRNAs was performed by using three algorithms, TargetScan, miRanda and Diana-microT [10-12].

For these target genes, we classified them according to the cell type and their known functions by using Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources 6.7 http://david.abcc.ncifcrf.gov [13]. Clustering of target genes according to cell types were based on CGAP SAGE tissue-specific library [14]. The pathway enrichment analysis was done using reactome database [15]. To visualize the miRNAs targeted genes and cell specific functional pathways, we input network dataset into CytoScape version 3.0.0 beta 1 available at http://www.cytoscape.org [16].

To perform a integrated analysis of the miRNA involved in atherosclerotic lesions, we downloaded the following microarray data from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) [17]: microarray data of macrophages from human ruptured plaque and stable plaque (GSE41571), coronary atherosclerotic artery and internal mammary artery IMA.
early versus advanced carotid plaque (GSE28829) [19], distant macroscopically intact tissue versus atheroma plaque (GSE43292) [20]. The raw data were analyzed by SAM and the significant differentially expressed genes (FDR < 0.05) were selected for further analysis. DAVID was used to analysis these genes’ enriched pathway with Reactome database. The network of integrated miRNA targets and plaque lesions upregulated gene enriched pathway were illustrated by CytoScape version 3.0.0 beta 1.

Results
Statin treatment changed miRNAome in the circulation of UA patients
MicroRNA TLDA was performed to compare miRNA expression profiles in the whole blood samples from UA patients treated with (n = 10) or without statin (n = 10) and plasma samples from UA patients treated with (n = 5) or without statin (n = 5). For these two groups of patients, no significant differences were observed in baseline conditions, medical histories, medications and the results of laboratory testings (Table 1). The miRNAs expression profiles were significantly different between these two groups (FDR < 0.001%) and 22 whole blood miRNAs and 19 plasma miRNAs were found significantly upregulated in the statin treatment group compared with the control group (Table 2). The whole analysis flow was presented in diagram. (Additional file 1: Figure S1) MiRNAs profile of the statin treatment group and the control group were illustrated in heatmap (Additional file 2: Figure S2).

Identification of the cell origins of statin induced circulating miRNAs
To reveal the possible cell/tissue origin(s) for these differentially expressed circulating miRNAs, we searched miRWalk database for the organs which could express these microRNAs. We found that mir-15b, mir-150, mir-19b, mir-106a, mir-222, mir-26a, mir-223, mir-30c, mir-451 and mir-92a were reported exist in monocyte. Mir-15b, mir-106a, mir-150, mir-191, mir-26a, mir-222, mir-223, mir-30b, mir-451, mir-92a and mir-93 can be expressed by macrophage. Mir-15b, mir-150, mir-222, mir-30b, mir-30c and mir-451 exist in platelet etc. In plasma, these MiRNAs were reported exited in monocyte mir-21, mir-24, mir-146b, mir-142-3p, mir-126, mir-20a, mir-146a, mir-19a, mir-126, mir-20a, mir-146a, mir-146b, mir-142-3p, mir-19a, mir-126, mir-20a, mir-146a,
mir-222, mir-223 and mir-106a in endothelial cell etc. (Additional file 3: Table S1). Thus, we can cluster these statin regulated miRNAs according to their cell origins.

Signaling pathways regulated by statin induced whole blood miRNAs

We predicted target genes regulated by these statin induced miRNAs by using three public algorithms: TargetScan, miRanda, and Diana-microT (Additional file 4: Table S2). To analysis the miRNA targets calculated by the three tools, we input each of 22 miRNA targets into DAVID bioinformatic tools. In order to analysis the whole blood miRNA specific in different cells. Target genes were separated into groups using serial analysis of gene expression (SAGE) database based on different cell types. We focused on atherosclerosis related cells, including monocytes, plaque macrophage, platelet, and endothelial cell. The target gene enriched pathways were analyzed in each specific cell type and visualized using cytoscape. We found that the target genes regulated by statin induced miRNA were enriched in the following pathways: (1) pathways of hemostasis, NGF (Nerve Growth Factor), membrane trafficking, opioid and PDGF (platelet-derived growth factor), in plaque macrophages; (2) pathways of hemostasis, Rho GTPases, integrin cell surface interactions, insulin receptor, and EGFR (epidermal growth factor receptor) in platelet; (3) Monocyte related pathway of signaling by NGF, Rho GTPases, apoptosis etc.; (4) Endothelial cell related signaling by NGF, hemostasis, apoptosis, PDGF etc. In general, the hemostasis pathway is the major one in macrophage and platelet; the Rho GTPases pathway is mainly regulated in monocyte and platelet.

Table 1 Characteristics of the study population treated with and without statin

|                          | Whole blood |          |          | Plasma    |          |          |
|--------------------------|-------------|----------|----------|-----------|----------|----------|
|                          | Control(n = 10) | Stain(n = 10) | p value | Control(n = 5) | Stain(n = 5) | p value |
| **General data**         |             |          |          |           |          |          |
| Sex, M/F                 | (4/6)       | (5/5)    | >0.99    | (3/2)     | (1/4)    | 0.524    |
| Age(yrs)                 | 59 ± 7.9    | 56 ± 7.6 | 0.394    | 59 ± 4.2  | 64 ± 9.9 | 0.343    |
| SBP(mm Hg)               | 135 ± 15.1  | 131 ± 15.6| 0.889    | 131 ± 12.1| 128 ± 16.4| 0.758    |
| DBP(mm Hg)               | 80 ± 7.1    | 82 ± 12.4| 0.591    | 78 ± 8.1  | 75 ± 11.2| 0.669    |
| **Medical history**      |             |          |          |           |          |          |
| Hypertension(%)          | 90(9/10)    | 80(8/10) | >0.99    | 60(3/5)   | 100(5/5)| 0.444    |
| Diabetes(%)              | 0(0/10)     | 0(0/10)  | >0.99    | 20(1/5)   | 20(1/5)| >0.99    |
| Hyperlipaemia(%)         | 30(3/10)    | 50(5/10) | 0.649    | 60(3/5)   | 100(5/5)| 0.444    |
| Cerebral vascular disease(%) | 0(0/10) | 0(0/10) | >0.99 | 0(0/5)   | 0(0/5)| >0.99    |
| Smoking(%)               | 20(2/10)    | 0(0/10)  | 0.474    | 40(2/5)   | 0(0/5)| 0.444    |
| **Laboratory test**      |             |          |          |           |          |          |
| Glucose(mmol/l)          | 5.4 ± 1.2   | 5.2 ± 1.4| 0.796    | 4.8 ± 0.6 | 5.1 ± 0.6| 0.526    |
| LDL cholesterol (mmol/l) | 2.5 ± 0.9   | 2.2 ± 0.9| 0.577    | 2.6 ± 0.7 | 2.4 ± 0.4| 0.605    |
| HDL cholesterol (mmol/l) | 1.0 ± 0.1   | 1.1 ± 0.3| 0.314    | 1.2 ± 0.3 | 0.8 ± 0.1| 0.034*   |
| TC (mmol/l)              | 4.3 ± 0.9   | 4.0 ± 1.1| 0.364    | 4.3 ± 0.5 | 3.9 ± 0.6| 0.462    |
| TG(mmol/l)               | 1.3 ± 0.6   | 1.2 ± 0.7| 0.496    | 1.6 ± 0.2 | 1.6 ± 0.3| 0.897    |
| Creatinine(mg/dl)        | 60.7 ± 13.5 | 62.5 ± 18.8| 0.781   | 76.2 ± 13.5| 62.0 ± 20.2| 0.781   |
| alt(u/l)                 | 28.9 ± 16.8 | 20.7 ± 9.2| 0.211    | 21.6 ± 17.2| 17.6 ± 5.3| 0.616    |
| ast(u/l)                 | 23.4 ± 11.2 | 18.1 ± 4.27| 0.224   | 18.8 ± 8.3 | 18.4 ± 2.3| 0.897    |
| **Medication**           |             |          |          |           |          |          |
| Aspirin(%)               | 30(3/10)    | 50(5/10) | 0.649    | 40(2/5)   | 60(3/5)| >0.99    |
| Clopidogrel(%)           | 30(3/10)    | 30(3/10) | >0.99    | 20(1/5)   | 60(3/5)| 0.524    |
| Calcium antagonists (%)  | 40(4/10)    | 20(2/10) | 0.628    | 40(2/5)   | 20(1/5)| >0.99    |
| ACEI/ARBs(%)             | 50(5/10)    | 20(2/10) | 0.349    | 0(0/5)    | 20(1/5)| >0.99    |
| β-Blockers(%)            | 20(2/10)    | 40(4/10) | 0.628    | 40(2/5)   | 40(2/5)| >0.99    |

SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. Comparisons between groups were performed with Student’s t test or Mann–Whitney U test for continuous variables and with the Fischer exact test or x² test for categorical variables. *p<0.05 versus control.
and the NGF pathway appear in all the cell types analyzed here.

Characterization of the pathways regulated by statin induced miRNA in atherosclerosis plaque

To reveal the function of statin induced miRNA in atherosclerotic plaque, we analyzed four microarray datasets related to atherosclerosis from GEO database, and the alteration of pathways in the atherosclerotic lesion group were selected by enrich analysis of significant upregulated gene (Additional file 5: Table S3). The statin upregulated miRNAs in whole blood and plasma exert its pharmaceutical function by inhibit the upregulated gene in lesions. To characterize the putative functions of the miRNAs, we identified the genes that were upregulated in the disease group. Then we generated the putative function networks targeted by these statin induced miRNAs in each of the four datasets. In the two coronary artery datasets, the two networks indicated that both type miRNAs majorly targeted the pathways of Rho GTPases, hemostasis, EGFR, synaptic transmission and opioid signaling (Figure 2a, b). Other evidence from the dataset of resident macrophage of ruptured plaque is that both miRNAs target pathways major in NGF, Rho GTPases, hemostasis and membrane trafficking (Figure 3a, b). In the two carotid atherosclerosis datasets, we also have miRNA target involved pathway overlap with upregulated pathway in disease status. The NGF signaling pathway, hemostasis and Rho GTPase signaling also emerged in the carotid plaque (Additional file 6: Figure S3a, b). The targets genes of statin induced miRNA target are also enriched in the hemostasis and Rho GTPase signaling in the advanced carotid plaque (Additional file 7: Figure S4a, b).

Moreover, we combined the previous four miRNA target networks (fig 3,4 supplement fig 3,4). Results indicated that the whole blood miRNAs target Rho GTPase and hemostasis which were commonly enriched in four lesions (Figure 4a). The plasma miRNAs integrated network the hemostasis and Rho GTPase pathway (Figure 4b). These results indicated that statin upregulated miRNA targets functionally enriched in the two pathways in the disease status.

Statin induced miRNA and their targets in Hemostasis and Rho GTPase pathways

From above analysis, hemostasis and Rho GTPase appeared to be two most important pathways targeted by

| Whole blood | Score(d) | Fold change | q-value(%) | Plasma | Score(d) | Fold change | q-value(%) |
|-------------|----------|-------------|------------|--------|----------|-------------|------------|
| hsa-miR-191 | 3.9826   | 2.0182      | <0.0001%   | hsa-miR-21 | 4.0676   | 9.6700      | <0.0001%   |
| hsa-miR-92a | 3.8634   | 2.6235      | <0.0001%   | hsa-miR-223 | 3.4159   | 8.6072      | <0.0001%   |
| hsa-miR-532-3p | 3.3904 | 2.4110      | <0.0001%   | hsa-miR-106a | 3.1782   | 5.9014      | <0.0001%   |
| hsa-miR-574-3p | 3.1517 | 2.7277      | <0.0001%   | hsa-miR-17 | 3.0701   | 5.7191      | <0.0001%   |
| hsa-miR-30b | 3.0671   | 2.2520      | <0.0001%   | hsa-miR-320 | 2.7697   | 7.9742      | <0.0001%   |
| hsa-miR-486-5p | 3.0474 | 2.2180      | <0.0001%   | hsa-miR-24 | 2.5543   | 5.1630      | <0.0001%   |
| hsa-miR-223 | 3.0328   | 2.3800      | <0.0001%   | hsa-miR-146b-5p | 2.4747 | 16.9902    | <0.0001%   |
| hsa-miR-30c | 2.9640   | 2.1134      | <0.0001%   | hsa-miR-142-3p | 2.4040 | 16.8645    | <0.0001%   |
| hsa-miR-484 | 2.9314   | 2.4529      | <0.0001%   | hsa-miR-19b | 2.3810   | 7.1494      | <0.0001%   |
| hsa-miR-451 | 2.8041   | 3.1920      | <0.0001%   | hsa-miR-19a | 2.2580   | 9.1338      | <0.0001%   |
| hsa-miR-331-3p | 2.6506 | 1.8440      | <0.0001%   | hsa-miR-30a-5 | 2.1183 | 9.2122      | <0.0001%   |
| hsa-miR-25 | 2.6181   | 2.3039      | <0.0001%   | hsa-miR-222 | 2.0399   | 8.4189      | <0.0001%   |
| hsa-miR-222 | 2.5022   | 2.0910      | <0.0001%   | hsa-miR-126 | 2.0359   | 7.1429      | <0.0001%   |
| hsa-miR-652 | 2.4739   | 2.4337      | <0.0001%   | hsa-miR-451 | 1.9745   | 9.8249      | <0.0001%   |
| hsa-miR-19b | 2.4250   | 2.0244      | <0.0001%   | hsa-miR-197 | 1.9738   | 2.7519      | <0.0001%   |
| hsa-miR-15b | 2.2769   | 2.2809      | <0.0001%   | hsa-miR-92a | 1.9470   | 6.4763      | <0.0001%   |
| hsa-miR-140-3p | 2.2018 | 1.9416      | <0.0001%   | hsa-miR-20a | 1.9312   | 6.8796      | <0.0001%   |
| hsa-miR-26a | 2.1192   | 2.3774      | <0.0001%   | hsa-miR-29a | 1.8389   | 4.4884      | <0.0001%   |
| hsa-miR-324-3p | 2.1131 | 1.8923      | <0.0001%   | hsa-miR-146a | 1.7932   | 7.7389      | <0.0001%   |
| hsa-miR-150 | 2.0946   | 1.7147      | <0.0001%   | hsa-miR-93 | 2.0697   | 2.4706      | <0.0001%   |
| hsa-miR-106a | 2.0101   | 2.2277      | <0.0001%   | hsa-miR-106a | 2.0101   | 2.2077      | <0.0001%   |

22 whole blood miRNAs and 19 plasma miRNAs were significantly different between the statin treatment group and the control group.
Figure 2 (See legend on next page.)
these statin induced miRNAs in plaque, therefore we further analyze these two pathways. We made a network of miRNAs and their targets in hemostasis pathway (Figure 5a, b), showing that both whole blood and plasma miRNAs target genes were mainly involved in interactions of cell surfaces on the vascular wall, platelet activation signaling and aggregation. On the other hand, in Rho GTPase signaling pathway, whole blood and plasma miRNAs targeted both the activator GEFS and inactivator GAPs and GDIs of the Rho GTPase. Furthermore the downstream effectors of the pathway were also targeted by certain miRNAs (Figure 6a, b).

Discussion

The benefits of Statins were caused by the inhibition of hydroxy-methyl-glutaryl-CoA (HMGCoA) reductase. Despite of the cholesterol lowering effect that ameliorated atherosclerotic plaque progression and reduced the adverse events in patients, accumulated evidence also showed that statins exerted pleiotropic effects [4,21-25]. In our study, the upregulated miRNAs downstream target in the specific cells most focused on the signaling pathway of NGF, Hemostasis, Rho GTPase and etc. As the circulating miRNAs could exert post-translation regulation in the target tissue, we preformed the miRNA and mRNA integrated analysis to describe statin induced miRNA function related to vascular disease. Previous studies have noticed the circulating microRNA have association with vascular disease [26,27]. We have analyzed the statin induced miRNAs which targeted the certain pathways, including the hemostasis, RhoGTPase and pathway in NGF rear reported in the atherosclerosis. Interestingly, our results are in accord with some previous findings such as hemostatis and rho kinase pathway [28,29]. From the systematic aspect, our bioinformatic findings and functional predictions could explain the novel mechanism by which miRNAs regulated post-translational repression of certain biologic process.

Several clinical and basic studies suggested that statin had non-cholesterol-dependent effect on hemostasis. For example, The PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial investigated high doses of statins in 4162 patients with acute coronary syndromes. The beneficial effect was independent of baseline LDL cholesterol and reached statistical significance [30]. In the JUPITER trial, rosuvastatin therapy was associated with decreased venous thromboembolism remarkably [31]. In a meta-analysis of the previous studies to investigate the efficacy of the immediate administration of statins in patients with acute coronary syndrome [32], the early beneficial effect was seen within acute phase (1 month). The significant reduction in clinical outcomes was associated with statin treatment, which played a potential role in antithrombosis. In mouse model, atorvastatin demonstrated an anticoagulation effect, which was induced by the reduction of platelet activation through upregulation of eNOS [33,34]. The abrupt withdrawal of statin abrogates the beneficial effect on endothelial function [4]. Furthermore, statins reduced tissue factor expression in macrophages and thereby inhibited the thrombotic interactions of the vascular wall [35]. We have noticed that the miRNA mostly inhibited the targets of hemostasis according to the bioinformatic analysis. It suggests that statin may act as an anticoagulant agent by increasing certain miRNA to inhibit coagulation. The specific aspect of miRNAs plays an important role in the process were mainly in signaling of the platelet activation and aggregation, and cell surface interactions on the vascular wall.

Meanwhile the association between Rho pathway and atherosclerotic lesions has long been studied. As the effectors of the small GTPase Rho, ROCKs have been shown to be upregulated in inflammatory arteriosclerotic lesions and to cause coronary vasospastic responses through inhibition of MLCP in both a porcine model of coronary artery spasm [36] and arteriosclerotic human arteries [37]. It has been suggested that ROCK induced NF-kB activation and subsequent T lymphocyte proliferation, which contributed to the development of early atherosclerosis [38]. Long-term inhibition of ROCKs caused a suppression of coronary arteriosclerosis and abrogation of coronary vasospastic activities in pig [39]. All the studies suggested that Rho GTPase signaling plays an important role in atherosclerosis, which was further demonstrated by our results that miRNA targeted the upregulated Rho GTPase pathway of coronary arteriosclerotic plaque and ruptured plaque. Moreover, ROCK1-deficiency mice in bone-marrow-derived cells exhibited a phenotype of decreased plaques size in LDL-receptor deficient background [4]. ROCK1 is predominantly upregulated in macrophages that were activated and adherent to endothelial cells during atherosclerosis. ROCK1-deficient macrophages decreased chemotaxis, cholesterol uptake, and foam-cell formation, which

Figure 2 MiRNA targeted the signaling pathways of upregulated genes in coronary atherosclerotic lesion. The data which compared coronary atherosclerotic plaque and IMA (internal mammary artery) were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR<0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway: A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.
Figure 3 MiRNA targeted the signaling pathways of upregulated genes from macrophages in ruptured atherosclerotic plaque. The data which compared macrophage in ruptured atherosclerotic plaque with in stable plaque were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR<0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.
resulted in regression of atherosclerotic lesions [40]. Our study suggested that circulating miRNA, which targeted Rho GTPase signaling, may also inhibit the plaque lesion. Thus, the anti-arteriosclerotic effect of statin may be partly due to the prevention of the activation of downstream Rho targets such as ROCKs [35]. Fluvastatin inhibited Rho in rat vascular smooth muscle cells, leading to the upregulation of iNOS expression [41]. Indeed, statins have been shown to inhibit Rho isoprenylation and ROCK activity. Statins can inhibit mevalonate synthesis, prevent membrane interaction of Rho, and suppress its subsequent activation of ROCKs [42]. Here we have provided a new aspect that miRNA reduced the RhoGTPase. MiRNA repressed target Rho GTPase signaling pathway involved in the plaque rupture. We showed that inhibition of Rho GTPase pathway appeared important in monocyte. Therefore, it is interesting to speculate whether some of the clinical benefits of statin therapy could be mediated by miRNA induced inhibition of the Rho GTPase pathways. On the other hand, the NGF signaling pathway and opioid pathway in our study are relatively new signaling pathways.
pathways in atherosclerosis. NGF signaling is involved in the survival, differentiation and plasticity of neurons in the peripheral and central nervous system, and opioid pathway has powerful analgesic and sedative effects. These two signaling pathways exert important function in the signal transmission in neurons. However, studies, which investigated these two pathways in atherosclerosis were few. NGF molecules decreased in the human coronary atherosclerotic plaque [43], and also reduced in the plasma of ACS patients [44]. The NGF signaling pathway, which was targeted by miRNA, may be also involved in the intervention of diseases. The pain of patients could be influenced by statin regulated miRNAs, which target in the opioid pathway. Further study is needed to unveil the potential effect of statin.

In summary, the combined data mining of miRNA and mRNA expression provided a putative mechanism to explain partial effect of statin that has been noticed.

Conclusions

MiRNAs array indicated that statin induced 22 miRNAs in whole blood and 19 miRNAs in plasma. Bioinformatic analysis of the miRNAs signature revealed that statin influenced different pathways in the atherosclerosis related cells. Together with data from atherosclerosis lesions, miRNAs were also involved in the development of atherosclerotic lesion by targeting Hemosatiss and Rho GTPases pathway. All the results provided systematic evidence for regulatory effect of statin in unstable angina patients. Bioinformatic analysis was used to find significantly upregulated miRNAs target genes. Those target genes were clustered based on SAGE genie and categorized into four cell types. Each cell specific genes were then functionally clustered according to Reactome pathway. The two steps were performed in DAVID functional clustering tools and the figure was generated using CytoScape. The pathway which was targeted by only one miRNA was not displayed.

The data which compared coronary atherosclerotic plaque and IMA (internal mammary artery) were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR < 0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.

The data which compared macrophage in ruptured atherosclerotic plaque with in stable plaque were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR < 0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.

The illustrated network was generated from the data of the miRNA target pathways in coronary atherosclerotic plaque, ruptured coronary plaque, carotid plaque and advanced carotid plaque. A. The network showed that the whole blood miRNA targeted Signaling by Rho GTPases and Hemostasis in the four atherosclerotic lesion. B. The network showed that the plasma miRNA targeted Signaling by Hemostasis and Rho GTPases in four atherosclerotic lesions.

MiRNA targets were predicted by targetscan, Miranda and DIANAmiT. The coronary plaque microarray data were analyzed by SAM and significantly differentially expressed genes were input into DAVID to select the hemostasis related genes. After integration of the miRNA targets genes and hemostasis related genes in the coronary plaque data, the miRNA target network was created to illustrate the mechanism how miRNAs were involved in the development of plaque. A: the network of whole blood miRNAs target genes. B: the network of plasma miRNAs target genes. The names of genes were official gene symbols. MicroRNAs with red border line are the miRNAs presents in the former network target the hemostasis. The yellow nodes are related with signaling of platelet activation and aggregation. The green nodes are related with formation of fibrin clot. The purple nodes are related with dissolution of fibrin clot. The blue nodes are related with cell surface interactions on the vascular wall.
Figure 6 MiRNA targeted upregulated genes of Rho GTPase signaling. MiRNA target was predicted by targetscan, Miranda and DIANAmT. The ruptured plaque microarray data were analyzed by SAM, and significantly differentially expressed genes were input into DAVID to select the hemostasis related gene. The miRNA targets and Rho GTPase related genes were integrated. A: the network of whole blood miRNAs target genes. B: the network of plasma miRNAs target genes. The names of genes were official gene symbols. MicroRNAs with red border line are the miRNAs present in the former network target the Rho GTPase pathway. The green node represents activation of Rho GTPase GDP by GEFs. The brown node represents activation of stream effector by Rho GTPase GTP. The blue node represents inactivation of Rho GTPase GTP by GAPs through hydrolysis. The purple node represents inactivation of Rho GTPase GDP by GDIs.
expressed genes were input into DAVID to select the hemostasis related gene. The miRNA targets and Rho GTPase related genes were integrated. A: the network of whole blood miRNAs target genes. B: the network of plasma miRNAs target genes. The names of genes were official gene symbols. MicroRNAs with red border line are the miRNAs presents in the former network target the Rho GTPase pathway. The green node represents activation of Rho GTPase GDP by GEFs. The brown node represents activation of Rho GTPase GTP by GAPs through hydrolysis. The purple node represents inactivation of Rho GTPase GDP by GEFs.

**Additional files**

**Additional file 1:** Figure S1. Study work flow diagram. Whole blood samples were collected from UA patients (n = 30) enrolled at Peking University People’s Hospital. TLD-A, TaqMan Low Density Arrays; SAM, Significance Analysis of Microarrays; CGAP SAGE, Cancer Genome Anatomy Project Serial Analysis of Gene Expression; GEO, Gene expression Omnibus.

**Additional file 2:** Profile of circulating miRNAs in non-statin group and statin group. A: Whole blood differential miRNAs profiles. B: plasma miRNAs differential miRNAs profiles. Heatmap displays the levels of significantly differential expressed miRNAs. Color intensity represents the expression value in each row, bright red indicates the high expression level and the bright green indicates the low expression level.

**Additional file 3:** Table S1. MiRNAs organ expression profile were generate from miRWalk database. The organ expression profiles of the miRNAs were based on published data.

**Additional file 4:** Table S2. Enriched pathways of the MiRNAs’ target genes. Target genes list of significant differential miRNAs predicted by TargetScan, miranda, and diana-microT.

**Additional file 5:** Table S3. Enriched pathways of upregulated genes in atherosclerosis lesions.

**Additional file 6:** Figure S3. MicroRNA target signaling pathway in the human carotid plaque. The data which compared human carotid plaque and intact carotid tissue were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR < 0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways, B: plasma miRNAs target pathways, Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.

**Additional file 7:** Figure S4. MicroRNA target signaling pathway in the human advance carotid plaque. The data which compared advance carotid plaque and early carotid plaque were obtained from GEO database. SAM was used to analyze the significantly differentially expressed genes (FDR < 0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways, B: plasma miRNAs target pathways. Illustration combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

HC contributed to the conception or design of the work; Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Final approval of the version to be published. JL carried out experiment, analysis, interpretation of data for the work. Drafting the work and revising it critically for important intellectual content, wrote the manuscript. JR contributed to the conception or design of the work and revising it critically for important intellectual content. JS, FZ contributed to revise the manuscript. JZ, CL, SL, QG, CC contributed to collect clinical samples and clinical data. NX contributed to revising it critically for important intellectual content. All authors read and approved the final manuscript.

**Acknowledgements**

We appreciated for funding that supported us, grant from National science and technology ‘creation of major new drugs’ (No. 2012ZXX09303019), Key program of Beijing science and technology project (D141100003014002), National Natural Science Foundation of China (81270274,81270276,H10206), Beijing Natural Science Foundation (7122198). We thank the Dr. Zhengguo Qiao and Dr. Guoping Han for technical support.

**Author details**

1. Department of Cardiology, Peking University People’s hospital, No. 11 Xizhimen South Street, Beijing 100044, China. 2. Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

**Received:** 16 December 2014 **Accepted:** 6 February 2015

**Published online:** 13 March 2015

**References**

1.  Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22(9):1452–8.
2.  Kleemann R, Prinzen HM, Emeis JJ, Jukema JW, Fontijn RD, Horevoets AJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003;108(11):1368–74.
3.  Schneider MP, Schmidt BM, John S, Schneider RE. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens. 2011;29(9):1757–64.
4.  Chen H, Ren JY, Xing Y, Zhang WL, Liu X, Wu P, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose–response effect dependent on endothelial nitric oxide synthase. Int J Cardiol. 2009;131(3):313–20.
5.  Takwi AA, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK, et al. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med. 2012;4(9):896–909.
6.  Scholer A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. MicroRNA-126-Sp promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368–76.
7.  Sun X, He S, Wai AK, Icli B, Bluvstein E, Tsenesitisky Y, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res. 2014;114(1):32–40.
8.  Dentellis P, Rosso A, Orso F, Olgaicì C, Taverna D, Brizzi MF. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol. 2010;30(8):1562–8.
9.  Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44(6):509–7.
10.  Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):192–105.
11.  Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36(Database issue): D149–53.
12.  Maragkakis M, Rizkimo S, Simossis VA, Alexiou P, Papadopoulos GL, Dalmanagias T, et al. diana-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 2009;37(Web Server issue): W273–6.
13.  da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A. 2002;99(17):11287–92.

Croft D, Mundo AF, Haw R, Milacic M, Weaver J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014;42(Database issue):D472–7.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.

Barrett T, Wilhite SE, Lodaux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991–5.

Hagg S, Skogsberg J, Lundstrom J, Noori P, Nilsson R, Zhong H, et al. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet. 2009;5(12):e1000754.

Doring Y, Mantaney HD, Drechsler M, Levene M, Megens RT, Soehnlein O, et al. Auto-antigenic protein–DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125(13):1673–83.

Ayari H, Briqa G. Identification of two genes potentially associated in iron-heme homeostasis in human carotid plaque using microarray analysis. J Biosci. 2013;38(2):311–5.

Bonaera A, Carmona G, Iwakami M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1703–5.

Hua Z, Lu Q, Ye W, Wong CK, Cai G, Du D, et al. miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006;e116.

Asanome A, Kawabe J, Matsuki M, Kabara M, Hira Y, Bochimoto H, et al. Nerve growth factor stimulates regeneration of peripheral nerve, and induces the maturation of microvessels around the injured artery. Biochem Biophys Res Commun. 2014;444(1):158–60.

Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124(6):720–30.

Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2012;110(1):71–81.

Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. BMC Med Genomics. 2013;6:16.

Wang J, Pei Y, Zhong Y, Jiang S, Shao J, Gong J. Altered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease. PLoS One. 2014;9(9):e107012.

Tanaka S, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013;33(7):1591–600.

Pastuszczak M, Kotara A, Mostowik M, Zalewski J, Zmudka K, Undas A. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res. 2010;125(3):382–6.

Mathers CD, Conlon D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

Glenny RJ, Danielson E, Fonseca FA, Genest J, Gotto Jr. AM, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–61.

Hulten E, Jackson JL, Douglass K, George S, Willens TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(17):1814–21.

Kandabashi T, Shimokawa H, Miyata K, Kunishio I, Kawanoto Y, Fukata Y, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101(11):1319–23.

Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunishio I, Morikawa K, et al. Involvement of rho-kinase in agonists-induced contractions of atherosclerotic human arteries. Arterioscler Thromb Vasc Biol. 2002;22(2):243–8.

Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, et al. Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary atherosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol. 2001;21(4):548–54.

Fox R, Nihan TQ, Law TL, Morris DR, Liles WC, Schwartz SM. PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J. 2007;26(2):505–15.

Chen H, Iida U, Shimo M, Iida M, Minota S, Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension. 2000;36(6):923–8.

Cicha I, Schneiderman-Mara N, Yilmaz A, Garluchs CD, Goppelt-Struebe M. Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo. Arterioscler Thromb Vasc Biol. 2004;24(11):2046–50.

Chaldakov GN, Fiore M, Stankulov G, Hristova M, Antonelli A, Manni L, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem. 2001;109(4):357–60.

Manni L, Nikolova V, Vagova D, Chaldakov GN, Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005;102(1):169–71.